Document:

EX-4.13
                  ADDITIONAL TRANSACTION LETTER

                  LA JOLLA COVE INVESTORS, INC.
                  1795 UNION STREET, 3rd FLOOR
                 SAN FRANCISCO, CALIFORNIA 94123
                  TELEPHONE:  (415) 409-8703
                 FACSIMILE:    (415) 409-8704
                   E-MAIL: LJCI@PACBELL.NET
LA JOLLA           www.LJCInvestors.com                  SAN FRANCISCO

June 22, 2006

Robert A. Hovee
World Am, Inc.
4040 MacArthur Boulevard, Suite 240
Newport Beach, CA 92660

Re: Additional Transactions

Dear Mr. Hovee:

Reference is made to the Convertible Debenture dated June 19, 2006
issued by World Am, Inc. ("World") to La Jolla Cove Investors, Inc.
("LJCI").  All terms used herein and not otherwise defined herein
shall have the definitions set forth in the Convertible Debenture.

The parties shall enter into an additional debenture and warrant to
purchase common stock, each on the same terms and conditions as the
Convertible Debenture and warrant.  The parties must enter into such
convertible debenture no later than thirty days after the Debenture
Principal Amount is less than $100,000 for the prior debenture.  In
the event that LJCI fails to enter into the additional debenture in
accordance with the terms of this paragraph, LJCI shall pay World
liquidated damages of $100,000. If World does not want LJCI to enter
into the additional debenture, World will pay LJCI liquidated damages
of $100,000.

Sincerely,

/s/  Travis W. Huff
Travis W. Huff
Portfolio Manager

World Am, Inc.

By: /s/  Robert A. Hovee
Robert A. Hovee
Chief Executive OfficerEXHIBIT 10.1

December 8,
2005

BETWEEN:

BIOJECT
MEDICAL TECHNOLOGIES INC.

AND:

EXECUTIVE

A
BIOJECT EXECUTIVE

CY05
RESTRICTED STOCK

UNIT GRANT AGREEMENT

 

BIOJECT RESTRICTED STOCK UNIT GRANT AGREEMENT

AND NOTICE OF GRANT

This
BIOJECT RESTRICTED STOCK UNIT GRANT AGREEMENT AND NOTICE OF GRANT (this “Agreement”)
is made as of the 8thth day of December, 2005 (the “Effective Date”). Capitalized Terms used in this Agreement, if
not otherwise defined, have the meanings given them in the Restated 1992
Stock Incentive Plan, as amended September 13, 2001 and March 13,
2003 (the “Plan”).

BETWEEN:

BIOJECT MEDICAL TECHNOLOGIES INC.

20245
SW 95th Ave

Tualatin,
Oregon  97062                                                                                                                              (“Company”)

AND:

EXECUTIVE                                                                                                                                         (“Participant”)

WHEREAS, the
Committee has selected the Participant to receive a Restricted Stock Unit Award
pursuant to the Plan; and

WHEREAS, the
Restricted Stock Unit Award provided in this Agreement is offered in
consideration for the Participant’s service with the Company, and the
Participant is willing to abide by the obligations imposed under this
Agreement;

NOW, THEREFORE, in
consideration of the mutual benefits hereinafter provided, and each intending
to be legally bound, the Company and the Participant hereby agree as follows:

1.                                       Grant Of Restricted Stock Units; Acceptance.

(a)           Subject
to the restrictions, terms and conditions of the Plan and this Agreement, the
Company hereby awards to the Participant XXX (XXX Restricted Stock Units (the “Award”),
with each unit representing the right to receive one share of the Company’s
Common Stock.

(b)           The
grant of Restricted Stock Units shall be null and void unless the Participant
shall accept this Agreement by executing it in the space provided below and
returning it to the Company.

2.                                       Delivery of Certificates Representing Stock Units.

(a)           The Company shall hold the Restricted Stock Units
in book-entry form. Subject to Section 6 and unless deferred by the
Participant, thirty (30) days following the vesting of the Restricted Stock
Units pursuant to Section 3 or thirty (30) days after the termination of
the Participant’s employment by the Company for any reason (each such date, the
“Issuance Date”), the Company shall issue to the Participant a stock
certificate representing a number of shares of Common Stock equal to the number
of vested Restricted Stock Units credited to Participant under this Agreement; provided, however, that
in the event of a Change in Control Event and regardless of whether the
Participant’s employment by the Company has terminated, the Issuance  Date 
shall be  within 10 days of the
occurrence of the Change  in Control. The
Company shall not be required to issue fractional shares of Common Stock upon
settlement of the Award.

(b)           The
Participant shall have no direct or secured claim in any specific assets of the
Company or the shares of Common Stock to be issued on the Issuance Date and
will have the status of a general unsecured creditor of the Company.

 2
 

 

3.             Vesting and Forfeiture.

(a)           Vesting Schedule-Award.
 Subject to the limitations contained
herein, the Restricted Stock Units shall vest as follows:

(i)                                     50%
of the Restricted Stock Units will vest one year from date of grant.

(ii)                                  50% will vest two years from date of grant.

Any Restricted Stock Units that do not vest for any
reason, for example, a service date is not reached or a performance level is
not reached, will be forfeited to the Company and will again be available for
issuance under the Plan.

(b)           Vesting Schedule-Change
in Control Units.

In the event there is a Change in Control Event as
defined in IRS Notice 2005-1 or any successor regulation, the Award
shall be deemed earned and 100% vested on the effective date of the Change in
Control Event.

A “Change in
Control Event” is defined for purposes of this Agreement as any of the
following events:

(i)            The approval by the shareholders of
the Company of:

(A)          any consolidation, merger or plan of
share exchange involving the Company (a “Merger”) as a result of which the
holders of outstanding securities of the Company ordinarily having the right to
vote for the election of directors (“Voting Securities”) immediately prior to
the Merger do not continue to hold at least 50% of the combined voting power of
the outstanding Voting Securities of the surviving or continuing corporation
immediately after the Merger, disregarding any Voting Securities issued or
retained by such holders in respect of securities of any other party to the
Merger;

(B)           any sale, lease, exchange or other
transfer (in one transaction or a series of related transactions) of all, or
substantially all, the assets of the Company; or

(C)           the adoption of any plan or proposal
for the liquidation or dissolution of the Company; or

(ii)                                  Any
“person” or “group” (within the meaning of Sections 13(d) and 14(d)(2) of
the Securities Exchange Act of 1934, as amended (the “Act”)) shall, as a result
of a tender or exchange offer, open market purchases or privately negotiated
purchases from anyone other than the Company, have become the beneficial owner
(within the meaning of Rule 13d-3 under the Act), directly or
indirectly, of Voting Securities representing fifty percent (50%) or more of
the combined voting power of the then outstanding Voting Securities.

(c)           Forfeiture.
As of the Effective Date, all of the Restricted Stock Units are subject to
forfeiture to the Company, without compensation, upon termination of the
Participant’s Continuous Service with the Company for any reason or no reason,
with or without cause. Restricted Stock Units that have not yet vested and are
subject to forfeiture without compensation are referred to in this Agreement as
“Unvested Units.”  Restricted Stock Units
that have vested and are no longer subject to forfeiture without compensation
(but remain subject to the other terms of this Agreement) are referred to in
this Agreement as “Vested Units.” 
Notwithstanding anything in this Agreement to the contrary, no
Restricted Stock Units will become Vested Units after the effective date of
termination of the Participant’s Continuous Service with the Company (the “Termination
Date”). There shall be no proportionate or partial vesting in the periods prior
to the applicable vesting dates and all vesting shall occur only on the
appropriate vesting date.

 3
 

 

(d)           Termination and
Termination Date. In
case of any dispute as to whether the Participant is terminated, the Committee
shall have sole discretion to determine whether the Participant has been
terminated and the Termination Date.

(e)           Adjustments.
If there is any change made in the Common Stock, without the receipt of
consideration by the Company (through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other
than cash, stock split, liquidating dividend, combination of shares, exchange
of shares, change in corporate structure or other transaction not involving the
receipt of consideration by the Company) occurring after the Effective Date, as
described in the Plan, then an adjustment shall be made to this Award so that
on the Issuance Date, the Participant shall receive such securities, cash
and/or other property as would have been received had the Participant held a
number of shares of Common Stock equal to the number of Restricted Stock Units
held by the Participant pursuant to this Award immediately prior to such change
or distribution, and such an adjustment shall be made successively each time
any such change shall occur.

4.             Restrictions on Transfers.

(a)           Restriction on Transfer. Participant shall not sell, assign,
transfer, pledge, hypothecate, or otherwise encumber or dispose of the
Restricted Stock Units that are subject to forfeiture pursuant to Section 3
until the restrictions on such Restricted Stock Units have lapsed or been
removed. Notwithstanding the foregoing, the Participant may transfer Restricted
Stock Units (i) by will or the laws or descent and distribution or (ii) pursuant
to beneficiary designation procedures approved by the Company.

(b)           Transferee Obligations. Each person (other than the Company)
to whom the Restricted Stock Units are transferred, as a condition precedent to
the validity of such transfer, shall acknowledge in writing to the Company that
such person is bound by the provisions of this Agreement to the same extent
such Restricted Stock Units would be so subject if retained by the Participant.

5.                                       Rights as Shareholder. This grant of Restricted Stock Units
does not confer upon the Participant any rights as a shareholder of the Company
(including, without limitation, voting and dividend rights) unless and only to
the extent shares of Common Stock are issued on the Issuance Date. The Company shall
credit the Participant with a number of Restricted Stock Units whose underlying
shares of Common Stock have a Fair Market Value equal to the dividend paid on
each share of Common Stock, multiplied by the total number of restricted stock
units subject to the Award described in this Agreement. Restricted Stock Units
issued in respect of dividend equivalents shall be subject to the same rules and
restrictions as Units originally subject to the Award.

6.                                       Withholding Taxes.

(a)           Withholding Tax Payment
Obligations. As a condition precedent to the delivery to the
Participant of any shares of Common Stock subject to the Award, the Participant
shall, upon request by the Company, pay to the Company such amount of cash as
the Company may be required, under all applicable federal, state, local or
other laws or regulations, to withhold and pay over as income or other
withholding taxes (the “Required Tax Payments”) with respect to the Award. If
the Participant shall fail to advance the Required Tax Payments after request
by the Company, the Company may, in its discretion, deduct any Required Tax
Payments from any amount then or thereafter payable by the Company to the
Participant.

(b)           Method of Payment. The Participant may elect to satisfy the
obligation to advance the Required Tax Payments by any of the following means: (1) a
cash payment to the Company pursuant to Section 6(a), (2) delivery
(either actual delivery or by attestation procedures established by the
Company) to the Company of previously owned whole shares of Common Stock (which
the Participant has good title, free and clear of all liens and encumbrances)
having a fair market value, determined as of the date the obligation to
withhold or pay taxes first arises in connection with the Award (the “Tax Date”),
equal to the Required Tax Payments, (3) authorizing the Company to
withhold from the shares of Common Stock otherwise to be delivered to the
Participant pursuant to the Award, a number of whole shares of Common Stock
having a fair market value, determined as of the Tax Date, equal to the
Required Tax Payments, (4) a cash payment 

 4
 

 

by a broker-dealer acceptable to the Company through
whom the Participant has sold the shares with respect to which the Required Tax
Payments have arisen, except as prohibited by Section 402 of the
Sarbanes-Oxley Act of 2002 or (5) any combination of (1), (2) and (3).
The Committee shall have sole discretion to disapprove of an election pursuant
to any of clauses (2)-(5). Shares of Common Stock to be delivered or withheld
may not have a fair market value in excess of the minimum amount of the
Required Tax Payments. Any fraction of a share of Common Stock that would be
required to satisfy such an obligation shall be disregarded and the remaining
amount due shall be paid in cash by the Participant. No certificate
representing a share of Common Stock shall be delivered until the Required Tax
Payments have been satisfied in full.

7.                                       Compliance with Laws and Regulations. The issuance and transfer of the
Shares will be subject to and conditioned upon compliance by the Company and
Participant with all applicable state and federal laws and regulations and with
all applicable requirements of any Exchange on which the Company’s Common Stock
may be listed at the time of such issuance or transfer.

8.                                       Successors and Assigns. The Company may assign any of its
rights under this Agreement. This Agreement shall be binding upon and inure to
the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this
Agreement will be binding upon Participant and Participant’s heirs, executors,
administrators, successors and assigns.

9.                                       No Right to Employment. Nothing
contained in this Agreement shall confer upon the Participant any right with
respect to the continuation of the Participant’s office or employment nor shall
anything contained in this Agreement interfere in any way with the right of the
Company to adjust Participant’s compensation from the level in existence at the
time of the grant hereof. Nothing contained in this Agreement shall interfere
in any way with the right of the Company or the Participant to terminate
Participant’s employment with the Company.

10.                                 Laws Applicable to Construction. The interpretation, performance and
enforcement of this Agreement shall be governed by the laws of the State of
Oregon. The parties agree that the forum for resolution of any dispute arising
out of, or relating to, the Agreement shall be by arbitration in Multnomah
County, Oregon in accordance with the provisions of the Arbitration Services of
Portland, Inc. The prevailing party will be entitled to recover from the
other party an amount determined reasonable as attorney fees.

11.                                 Notices. Any notice to be given under the terms of this Agreement shall
be addressed to the Company in care of its President or Secretary at its office
in Portland, Oregon, and any notice to be given to the Participant shall be
addressed to the Participant at the address given on the first page of this
Agreement, or at such other address as either party may hereafter designate in
writing to the other. Any such notice shall have been duly given when enclosed
in a properly sealed envelope addressed as aforesaid, registered or certified,
and deposited (postage and registry or certification fee prepaid) in a post
office branch regularly maintained by the Government of the jurisdiction in
which the notice is mailed.

12.                                 Further Instruments. The parties agree to execute such
further instruments and to take such further action as may be reasonably
necessary to carry out the purposes and intent of this Agreement.

13.                                 Headings. The captions and headings of this Agreement are included for
ease of reference only and will be disregarded in interpreting or construing
this Agreement. All references
herein to Sections will refer to Sections of this Agreement.

14.                                 Agreement Subject to Plan. The Award and this Agreement are subject to all the provisions of the Plan, the
provisions of which are hereby made a part of this Agreement, and are further
subject to all interpretations, amendments, rules and regulations which
may from time to time be promulgated and adopted pursuant to the Plan. In the
event of any conflict between the provisions of this Agreement and those of the
Plan, the provisions of the Plan shall control. Participant, by
execution hereof, acknowledges receipt of the Plan and any interpretations, amendments, rules and
regulations adopted pursuant to the Plan as they currently exist and
acceptance of the terms and conditions of the Plan, such interpretations, amendments, rules and
regulations and of this Agreement.

 5
 

 

IN
WITNESS WHEREOF, the Company has caused this Agreement to be executed in
duplicate by its duly authorized representative and Participant has executed
this Agreement in duplicate, as of the Execution Date.

	
  BIOJECT MEDICAL TECHNOLOGIES INC.

  	
   

  	
   

  
	
  By:

  	
   

  	
             

  	
   

  	
   

  
	
  Christine M.
  Farrell

  	
   

  	
   

  
	
  Controller and
  Secretary

  	
   

  	
   

  
	
  PARTICIPANT

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  EXECTUIVE

  	
   

  	
   

  
	
  SSN

  	
   

  	
   

  
					

 

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]